BioAgilytix
BioAgilytix is a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development. With laboratory locations in North Carolina’s Research Triangle Park; Cambridge, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of therapeutics across industries and disease states.
Strategies for Overcoming Drug Interference in Immunogenicity Assessment
ADA Assessment for Cell Therapies
Total Bioanalytical Support for Antibody−Drug Conjugates (ADCs)
PK Assessment for Advanced Modalities (Cell and Gene Therapies)
Immediate hypersensitivity reactions against biologicals
What the new AAPS White Paper recommends for immunogenicity assays supporting biosimilars
Recent aspects and challenges in the assessment of immunogenicity
Webinar Q&A follow up – Clinical relevance of (unwanted drug-induced) immune responses
Clinical relevance of (unwanted drug-induced) immune responses
Bioanalytical methods in support of biosimilar drug development
Overcoming Bioanalytical Hurdles In The Pharma And Life Sciences Sector
BioAgilytix and Sword Bio partner to improve immunoassay services
Evaluating the Immunogenicity of Antibody-Drug Conjugates
Exploratory Biomarker Testing: to Qualify or Validate the Assay?
Modern Challenges of Single and Multiplex Biomarker Validation
Immuno-oncology in 2018: Overcoming Challenges to Revolutionize Cancer Treatment
CAR T-Cell Therapy: Changing the Way Cancer is Treated
Strategies for Development and Validation of Neutralizing Antibody Assays Supporting Biosimilars
BioAgilytix appoints Nathan Speicher as Chief Financial Officer
BioAgilytix appoints Christie Knittel Mabry as new Chief People Officer
BioAgilytix Appoints Euan Menzies as Chairman and Chief Executive Officer
BioAgilytix announces the launch of COVIDenceTM
BioAgilytix Announces Extensive Facilities Expansion Plan at Its USA Headquarters
Panel discussion: lessons learnt from COVID-19 and lab 4.0
Panel discussion: ICH M10 draft bioanalytical method validation guideline
Panel discussion: new technology integration in bioanalytical workflows
Pharmacokinetic Bioequivalence of ATI-0918 and DOXIL®/CAELYX® in Patients with Ovarian Cancer
Efficient and Economical Preclinical Pharmacokinetic Analyses
In the Zone: ADA assessment and detection
Infographic: the facts about anti-drug antibodies
Is ISR Needed For Biomarker Assays? – Bioanalytical Lab & Top CRO for Large Molecule Bioanalysis
Determining Immunogenicity for CAR-T cell Therapies – Bioanalytical Lab & Top CRO for Large Molecule
Making an Impact: Biomarkers Inform the Drug Development Process for Large and Small Molecule Drugs
Clinical relevance of immunogenicity: an interview with Arno Kromminga
Exploratory biomarker testing: to qualify or validate the assay?
Evaluating the immunogenicity of antibody–drug conjugates
Biologics Market Growth Demands Quality Science that Can Keep Pace
Proof of Concept to Solution: A Unique Approach to Anti-PEG Antibodies Assessment
Website: www.bioagilytix.com
Email: [email protected]
Telephone: 919-381-6097
Address: 2300 Englert Drive, Durham, NC, 27713, USA